Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-924 HD versus pitavastatin 4 mg in hypercholesterolemia inadequately controlled on pitavastatin
jRCT2031260377Phase 3Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing K-924 HD arm with Pitavastatin 4 mg active-control arm (2 arms). Primary endpoints: Percent change from baseline in LDL-C at Week 12 and Adverse events and adverse drug reactions. Started Sep 2026; status: recruiting.
02
Drugs
pitavastatin + ezetimibepitavastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2031260377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260377.